SNPHY OTC
Santen Pharmaceutical Co., Ltd.
1W: -3.4%
1M: -6.1%
3M: -24.1%
YTD: -1.9%
1Y: -1.7%
3Y: +18.1%
5Y: -22.5%
$10.55
-0.57 (-5.13%)
Weekly Expected Move ±6.1%
$9
$10
$11
$11
$12
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$46.1B
-24.3% ▼
5Y CAGR: +3.5%
Capital Expenditures
$7.3B
-8.9% ▼
5Y CAGR: -21.1%
Free Cash Flow
$38.9B
-28.4% ▼
5Y CAGR: +21.0%
Dividends Paid
$13.4B
-10.7% ▼
Buybacks
$34.8B
+8.2% ▲
Net Change in Cash
-$18.1B
-119.5% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $27.2B | -$15.0B | $26.6B | $36.3B | $39.6B |
| Depreciation & Amort. | $17.1B | $17.2B | $18.2B | $17.9B | $19.5B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | $4.7B | -$5.1B | $14.2B | $10.2B | -$13.6B |
| Other Non-Cash Items | -$2.9B | $39.9B | $13.7B | -$3.5B | $603M |
| Operating Cash Flow | $46.0B | $37.1B | $72.6B | $60.9B | $46.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$35.8B | -$24.6B | -$9.3B | -$6.7B | -$15.1B |
| Acquisitions (Net) | -$3.0B | -$3.5B | -$207M | $0 | $0 |
| Investment Purchases | -$1.1B | -$589M | -$301M | $0 | -$225M |
| Investment Sales | $3.9B | $2.1B | $4.1B | $0 | $606M |
| Other Investing | $838M | -$279M | -$445M | -$1.6B | $988M |
| Investing Cash Flow | -$35.2B | -$26.8B | -$6.1B | -$8.2B | -$13.8B |
| — Financing Activities — | |||||
| Net Debt Issuance | $20.5B | $4.4B | -$2.1B | -$3.3B | $0 |
| Stock Repurchased | -$12M | -$26.0B | -$17.0B | -$37.9B | -$34.8B |
| Dividends Paid | -$12.0B | -$12.6B | -$11.9B | -$12.1B | -$13.4B |
| Other Financing | -$2.9B | -$3.0B | -$3.1B | $0 | -$4.1B |
| Financing Cash Flow | $5.6B | -$37.2B | -$34.0B | -$53.3B | -$52.3B |
| Net Change in Cash | $20.1B | -$25.1B | $36.7B | $93.0B | -$18.1B |
| Cash End of Period | $83.0B | $57.9B | $94.6B | $93.0B | $81.2B |
| Free Cash Flow | $10.2B | $12.6B | $62.0B | $54.3B | $38.9B |